These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 17869515

  • 1. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.
    Dominguez C, Smith L, Huang Q, Yuan C, Ouyang X, Cai L, Chen P, Kim J, Harvey T, Syed R, Kim TS, Tasker A, Wang L, Zhang M, Coxon A, Bready J, Starnes C, Chen D, Gan Y, Neervannan S, Kumar G, Polverino A, Kendall R.
    Bioorg Med Chem Lett; 2007 Nov 01; 17(21):6003-8. PubMed ID: 17869515
    [Abstract] [Full Text] [Related]

  • 2. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
    Zhao G, Peery RB, Yingling JM.
    Anal Biochem; 2007 Jan 15; 360(2):196-206. PubMed ID: 17141171
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC.
    J Med Chem; 2008 Mar 27; 51(6):1695-705. PubMed ID: 18311900
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.
    Cancer Res; 2009 Oct 15; 69(20):8009-16. PubMed ID: 19808973
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
    Ryu J, Lee CW, Hong KH, Shin JA, Lim SH, Park CS, Shim J, Nam KB, Choi KJ, Kim YH, Han KH.
    Cardiovasc Res; 2008 May 01; 78(2):333-40. PubMed ID: 18006432
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
    Bauer D, Whittington DA, Coxon A, Bready J, Harriman SP, Patel VF, Polverino A, Harmange JC.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4844-8. PubMed ID: 18682324
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE.
    Cancer Res; 2008 Mar 01; 68(5):1581-92. PubMed ID: 18316624
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
    McDermott LA, Simcox M, Higgins B, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Luk KC.
    Bioorg Med Chem; 2005 Aug 15; 13(16):4835-41. PubMed ID: 15953730
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery of novel taspine derivatives as antiangiogenic agents.
    Zhang J, Zhang Y, Zhang S, Wang S, He L.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):718-21. PubMed ID: 20006929
    [Abstract] [Full Text] [Related]

  • 19. Investigating the differential activation of vascular endothelial growth factor (VEGF) receptors.
    Horta BA, Sodero AC, de Alencastro RB.
    J Mol Graph Model; 2009 Oct 15; 28(3):287-96. PubMed ID: 19734078
    [Abstract] [Full Text] [Related]

  • 20. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
    Gaudette F, Raeppel S, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Macleod AR, Besterman JM, Vaisburg A.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):848-52. PubMed ID: 20071170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.